Efficacy and safety of factor Xa inhibitors in low body weight patients
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2024
DOI: 10.1002/phar.2888 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2024. Verfasst von Yingcong Tan und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Ascension St. John Hospital, Detroit, Michigan, USA. Hauptthemen laut MEDLINE: Atrial Fibrillation, Venous Thromboembolism, Stroke. Die Arbeit nennt 16 Literaturangaben.
Abstract (Originalsprache)
Study Objective The purpose of this study is to provide evidence for the safety and efficacy of factor Xa inhibitors in patients with a weight ≤60 kg or BMI < 18.5 kg/m 2 .
Design
Multicenter, retrospective, cohort study.
Setting
Twenty‐two Ascension Health hospitals. Patients Low‐body‐weight adult patients (weight ≤ 60 kg or BMI < 18.5 kg/m 2 ) receiving treatment for atrial fibrillation or venous thromboembolism.
Intervention
Factor Xa inhibitors (apixaban or rivaroxaban) or warfarin. Measurements and Main Results This study included 2538 patients between the factor Xa inhibitors ( n = 1695) and warfarin ( n = 843) groups with a mean weight of 53.5 ± 5.5 kg and BMI of 20.7 ± 3.1 kg/m 2 . No significant difference in time to major bleeding was noted after controlling for potential confounders (HR 1.03, 95% CI 0.70–1.53, p = 0.87); similar results were seen following propensity score matching. Thromboembolism (5.3% vs. 6.2%, p = 0.38), composite major + clinically relevant nonmajor bleeding (9.8% vs. 11.5%, p = 0.18), and all‐cause mortality (10.7% vs. 12.8%, p = 0.12) were similar between patients receiving factor Xa inhibitors versus warfarin.
Conclusion
No differences in safety or effectiveness were noted between factor Xa inhibitors versus warfarin. These findings provide encouraging evidence to support the use of factor Xa inhibitors in low‐body‐weight patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Ascension St. John Hospital, Detroit, Michigan, USA.
- Department of Pharmacy, Ascension Genesys Hospital, Grand Blanc, Michigan, USA.
- Department of Pharmacy, Ascension Saint Thomas Hospital Midtown, Nashville, Tennessee, USA.
- Department of Pharmacy, Ascension St. Vincent's, Birmingham, Alabama, USA.
- Eugene Applebaum College of Pharmacy & Health Sciences, Wayne State University, Detroit, Michigan, USA.
ORCID-Profile: Stephanie B Edwin
Zitieren
APA
Tan, Y., Hubbard, C., Owens, H., Pitt, J., Giuliano, C., Haan, B., Breeden, T., Sirbu, D., Pena, K., Haddox, T., & Edwin, S. B. (2024). Efficacy and safety of factor Xa inhibitors in low body weight patients. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. https://doi.org/10.1002/phar.2888
Vancouver
Tan Y, Hubbard C, Owens H, Pitt J, Giuliano C, Haan B, et al. Efficacy and safety of factor Xa inhibitors in low body weight patients. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2024. doi:10.1002/phar.2888
BibTeX
@article{Tan2024,
author = {Tan, Yingcong and Hubbard, Cynthia and Owens, Holly and Pitt, James and Giuliano, Christopher and Haan, Bradley and Breeden, Thomas and Sirbu, Dumitru and Pena, Kelsey and Haddox, Trevlyn and Edwin, Stephanie B},
title = {Efficacy and safety of factor Xa inhibitors in low body weight patients},
journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
year = {2024},
doi = {10.1002/phar.2888}
}
EUVIMED